DAVID POPLACK to Topotecan
This is a "connection" page, showing publications DAVID POPLACK has written about Topotecan.
Connection Strength
0.197
-
Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis. J Clin Oncol. 2003 Jan 01; 21(1):143-7.
Score: 0.053
-
New cytotoxic drugs for intrathecal administration. J Neurooncol. 1998 Jun-Jul; 38(2-3):219-23.
Score: 0.038
-
Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study. Clin Cancer Res. 1998 Feb; 4(2):357-60.
Score: 0.037
-
Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. Cancer Res. 1993 Mar 01; 53(5):1032-6.
Score: 0.027
-
Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates. Cancer Res. 1993 Feb 15; 53(4):725-7.
Score: 0.026
-
Phase II evaluation of topotecan for pediatric central nervous system tumors. Cancer. 1996 Aug 01; 78(3):527-31.
Score: 0.008
-
Intrathecal administration of topotecan in nonhuman primates. Cancer Chemother Pharmacol. 1995; 36(2):121-4.
Score: 0.008